



## Therapeutic Agents for Neurological Disorders 2022

Guest Editor:

### **Dr. Damian Holsinger**

Neuroscience, School of Medical  
Sciences, Faculty of Medicine and  
Health, The University of Sydney,  
Camperdown, NSW, Australia

Deadline for manuscript  
submissions:

**closed (31 August 2022)**

### **Message from the Guest Editor**

The World Health Organization defines neurological disorders as disabling conditions that encompass, but are not limited to, cerebrovascular diseases, epilepsy, dementias, including Alzheimer's, multiple sclerosis, movement disorders resulting from nervous system deficits, brain tumors, neuroinfections and neurological disorders as a result of malnutrition. These figures outline an impending epidemic that requires urgent attention. Treatments for neurological disorders are challenging, but numerous advancements have been made in identifying mechanisms and delineating the pathways underlying these diseases. Advances in technologies that garner information from the fields of bioinformatics and next generation and whole genome sequencing have added invaluable support in identifying "culprit" genes and proteins. Using this information, scientists and clinicians have ventured into areas previously deemed "fiction". In this Special Issue, we aim to draw together research from experts in the field that highlight therapeutic agents and strategies, as well as identify future directions that will lead to discoveries and therapies for neurological disorders.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)